Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin

Oncology Research

Volumn 20, Issue 1, 2012, Pages 25-30

  Ryu, Jeong Seon ^a   Kim, Hyun Jung ^a   Shin, Eun Soon ^b   Nam, Hae Seong ^a   Cho, Jae Hwa ^a   Lee, Jong Eun ^b  

^a Inha University Hospital   (South Korea)

^b NA Link   (South Korea)

Author keywords

Deoxycytidine kinase; Gemcitabine; Lung cancer; Pharmacogenetics; Polymorphism

Indexed keywords

ALANINE; CISPLATIN; CYSTEINE; DEOXYCYTIDINE KINASE; GEMCITABINE; GLYCINE; THREONINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HAZARD RATIO; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TAGGING SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84865465698     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504012X13425470196137     Document Type: Article

References (18)

1. Schiller, J. H.; Harrington, D.; Belani, C. P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:92-98; 2002.
2. Smit, E. F.; van Meerbeeck, J. P.; Lianes, P.; Debruyne, C.; Legrand, C.; Schramel, F.; Smit, H.; Gaafar, R.; Biesma, B.; Manegold, C.; Neymark, N.; Giaccone, G. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J. Clin. Oncol. 21:3909-3917; 2003.
3. Kocabas, N. A.; Aksoy, P.; Pelleymounter, L. L.; Moon, I.; Ryu, J. S.; Gilbert, J. A.; Salavaggione, O. E.; Eckloff, B. W.; Wieben, E. D.; Yee, V.; Weinshilboum, R. M.; Ames, M. M. Gemcitabine pharmacogenomics: Deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab. Dispos. 36:1951-1959; 2008.
4. Wong, A.; Soo, R. A.; Yong, W. P.; Innocenti, F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab. Rev. 41:77-88; 2009.
5. Kroep, J. R.; Loves, W. J.; van der Wilt, C. L.; Alvarez, E.; Talianidis, I.; Boven, E.; Braakhuis, B. J.; van Groeningen, C. J.; Pinedo, H. M.; Peters, G. J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1:371-376; 2002.
6. Bergman, A. M.; Pinedo, H. M.; Peters, G. J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Update 5:19-33; 2002.
7. Sebastiani, V.; Ricci, F.; Rubio-Viqueira, B.; Kulesza, P.; Yeo, C. J.; Hidalgo, M.; Klein, A.; Laheru, D.; Iacobuzio-Donahue, C. A. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin. Cancer Res. 12:2492-2497; 2006.
8. Mey, V.; Giovannetti, E.; De Braud, F.; Nannizzi, S.; Curigliano, G.; Verweij, F.; De Cobelli, O.; Pece, S.; Del Tacca, M.; Danesi, R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br. J. Cancer 95:289-297; 2006.
9. Ferrandina, G.; Mey, V.; Nannizzi, S.; Ricciardi, S.; Petrillo, M.; Ferlini, C.; Danesi, R.; Scambia, G.; Del Tacca, M. Expression of nucleoside transporters, deoxy-citidine kinase, ribonucleotide reductase regulatory sub-units, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother. Pharmacol. 65:679-686; 2009.
10. Seve, P.; Mackey, J. R.; Isaac, S.; Tredan, O.; Souquet, P. J.; Perol, M.; Cass, C.; Dumontet, C. cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer 49: 363-370; 2005.
11. Okazaki, T.; Javle, M.; Tanaka, M.; Abbruzzese, J. L.; Li, D. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin. Cancer Res. 16:320-329; 2010.
12. Tanaka, M.; Javle, M.; Dong, X.; Eng, C.; Abbruzzese, J. L.; Li, D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116:5325-5335; 2010.
13. Soo, R. A.; Wang, L. Z.; Ng, S. S.; Chong, P. Y.; Yong, W. P.; Lee, S. C.; Liu, J. J.; Choo, T. B.; Tham, L. S.; Lee, H. S.; Goh, B. C.; Soong, R. Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer 63:121-127; 2009.
14. Kim, H. T.; Lee, J. E.; Shin, E. S.; Yoo, Y. K.; Cho, J. H.; Yun, M. H.; Kim, Y. H.; Kim, S. K.; Kim, H. J.; Jang, T. W.; Kwak, S. M.; Kim, C. S.; Ryu, J. S. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J. Clin. Oncol. 26:5972-5979; 2008.
15. Shi, J. Y.; Shi, Z. Z.; Zhang, S. J.; Zhu, Y. M.; Gu, B. W.; Li, G.; Bai, X. T.; Gao, X. D.; Hu, J.; Jin, W.; Huang, W.; Chen, Z.; Chen, S. J. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14:759-768; 2004.
16. Rivero, A.; Rapado, I.; Tomas, J. F.; Montalban, C.; de Ona, R.; Paz-Carreira, J.; Canales, M.; Martinez, R.; Sanchez-Godoy, P.; de Sevilla, A. F.; de la Serna, J.; Martinez-Lopez, J. Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma. Leuk. Res. 35:431-437; 2011.
17. Goan, Y. G.; Zhou, B.; Hu, E.; Mi, S.; Yen, Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59:4204-4207; 1999.
18. Kim, S. R.; Saito, Y.; Maekawa, K.; Sugiyama, E.; Kaniwa, N.; Ueno, H.; Okusaka, T.; Ikeda, M.; Morizane, C.; Yamamoto, N.; Yoshida, T.; Kamatani, N.; Furuse, J.; Ishii, H.; Saijo, N.; Ozawa, S.; Sawada, J. Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab. Pharmacokinet. 23:379-384; 2008.